NCT06703658View on ClinicalTrials.gov

A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 2, 2024

Primary Completion Date

March 13, 2025

Study Completion Date

March 13, 2025

Conditions
Healthy ParticipantsType 2 Diabetes
Interventions
DRUG

AZD5004(Part A)

Single dose of AZD5004 oral on Day1

DRUG

Placebo(Part A)

Single dose of placebo oral on Day1

DRUG

AZD5004(Part B)

AZD5004 will be administered as an oral tablet once daily.

DRUG

Placebo(Part B)

Placebo will be administered as an oral tablet once daily.

Trial Locations (1)

532-0003

Research Site, Osaka

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY